Bulletin
Investor Alert

New York Markets Close in:

Market Pulse Archives

June 25, 2021, 8:31 a.m. EDT

Roche's arthritis drug gets authorized as COVID-19 treatment for the severely ill

new
Watchlist Relevance
LEARN MORE

Want to see how this story relates to your watchlist?

Just add items to create a watchlist now:

  • X
    Roche Holding AG (ROG)
  • X
    S&P 500 Index (SPX)

or Cancel Already have a watchlist? Log In

By Jaimy Lee

Shares of Roche Holding Group /zigman2/quotes/206324342/delayed CH:ROG +0.35% were up 0.1% in trading on Friday, the day after the company said its COVID-19 drug has been authorized in the U.S. as a treatment for those who have been hospitalized with COVID-19 who are at least two years old. The drug, Actemra, is already approved by the Food and Drug Administration as a treatment for rheumatoid arthritis. The intravenous therapy is reserved for the very ill, including those patients already taking steroids, on oxygen, or being ventilated. Roche's stock is up 7.0% for the year, while the broader S&P 500 /zigman2/quotes/210599714/realtime SPX -0.24% has gained 13.0%.

/zigman2/quotes/206324342/delayed
CH : Switzerland: SWX
CHF 354.00
+1.25 +0.35%
Volume: 780,577
Aug. 4, 2021 5:31p
P/E Ratio
21.79
Dividend Yield
2.57%
Market Cap
CHF308.04 billion
Rev. per Employee
CHF574,809
loading...
/zigman2/quotes/210599714/realtime
US : S&P US
4,412.40
-10.75 -0.24%
Volume: 1.48B
Aug. 4, 2021 2:09p
loading...

Get news alerts on S&P 500 Index — or create your own.
This Story has 0 Comments
Be the first to comment
More News In
Industries

Story Conversation

Commenting FAQs »

Partner Center

Link to MarketWatch's Slice.